Capivasertib and Cyclosporine Ophthalmic: Interaction Details
AI-assisted, pharmacist-reviewed · Source data updated Aug 8, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Capivasertib
Cyclosporine Ophthalmic
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
What happens
Increased capivasertib exposure and an increased risk of capivasertib-related adverse reactions
Interaction Deep Dive
When capivasertib (a CYP3A substrate) and moderate CYP3A inhibitors are coadministered, reduce the dosage of capivasertib to 320 mg orally twice daily for 4 days followed by 3 days off and monitor patients for adverse reactions. After discontinuation of a moderate CYP3A inhibitor, resume the capivasertib dosage (after 3 to 5 half-lives of the inhibitor) that was taken prior to initiating the moderate CYP3A inhibitor. Moderate CYP3A inhibitors increase capivasertib exposure which may increase the risk of capivasertib adverse reactions1.
Why it happens (mechanism)
Inhibition of CYP3A-mediated metabolism of capivasertib
Literature reports
1 report — tap to read
a) Capivasertib Cmax is predicted to increase by 1.3-fold and AUC by 1.5-fold following concomitant use with erythromycin and verapamil (moderate CYP3A inhibitors) 1.
Common questions
Can I take Capivasertib and Cyclosporine Ophthalmic together?
Increased capivasertib exposure and an increased risk of capivasertib-related adverse reactions Always confirm with your pharmacist or prescriber before making any change.
How serious is the Capivasertib and Cyclosporine Ophthalmic interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "probable". Good supporting evidence, though not definitively proven.
Questions for your pharmacist
- Does my dose of Capivasertib or Cyclosporine Ophthalmic need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: TRUQAP(TM) oral tablets, capivasertib oral tablets. AstraZeneca Pharmaceuticals LP (per FDA), Wilmington, DE, 2023. DailyMed
Keep reading about Capivasertib
Keep reading about Cyclosporine Ophthalmic
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist